SCHEMBL2375600

SCHEMBL2375600

Cc1cc2c(cc1-c1cccc(C#N)c1)C(=O)CC1(CCCOC1)O2

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.41
KDM4E B2RXH2 2/20 0.40
ATM Q13315 3/20 0.39
HTT P42858 1/20 0.39
LRRK2 Q5S007 2/20 0.35
BACE1 P56817 5/20 0.34
CTSD P07339 1/20 0.34
HTR2A P28223 1/20 0.34
CTSB P07858 1/20 0.34
APP P05067 2/20 0.34
CREBBP Q92793 1/20 0.34
ACACB O00763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378075 0.86 LRRK2 (0.35) PGRLRRK2BACE1CTSDCTSB
SCHEMBL2378073 0.86 LRRK2 (0.35) PGRLRRK2BACE1CTSDCTSB
SCHEMBL1822792 0.74 KDM4E (0.47) KDM4EATMHTTACACB
SCHEMBL1822380 0.73 PGR (0.50) PGRKDM4EATMHTTBACE1
SCHEMBL1828231 0.73 BACE1 (0.54) BACE1APP
SCHEMBL12246417 0.72 PGR (0.47) PGRKDM4EATMHTTBACE1
SCHEMBL7958327 0.72 PGR (0.47) PGRKDM4EATMHTTBACE1
SCHEMBL2377088 0.72 PGR (0.47) PGRKDM4EATMHTTBACE1
SCHEMBL2376869 0.72 PGR (0.47) PGRKDM4EATMHTTBACE1
SCHEMBL12299672 0.71 KDM4E (0.49) KDM4EATMHTTBACE1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP PGR 4654/4885KDM4E 3004/4885ATM 4610/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP PGR 4654/4885KDM4E 3004/4885ATM 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.